Published: January 2022

Gone are the days where a type 1 diabetes diagnosis meant a lifetime of finger pricking and injections. Today, almost half of the 4 million Americans living with type 1 diabetes use devices called continuous glucose monitors, or CGMs, to monitor their glucose levels and regulate their insulin levels in real-time.

While uptake of CGM so far has been concentrated in the care of people with type 1 diabetes, CGMs are increasingly being prescribed to a much larger group – those 40 million plus Americans living with type 2 diabetes. And, as the market for CGMs grows — to a $5 billion market in 2021, by some estimates — so  too does the optimism that they will help manage the flood of unmanaged type 2 diabetes.

In our latest report, written by STAT’s Katie Palmer, we’ve gathered our best intelligence on the burgeoning industry of CGM, and where it’s likely to head next.

How it works

Add this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.

Preview

Take a peek at what's included in this report.